BioSpace News Archive

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract titles and authors for two posters that will be presented at the AACR-NCI-EORTC Virtual International Conference.

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle® Toxin Conjugate (BTC™) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference.

Acclarent, Inc., part of the Johnson & Johnson Medical Devices Companies,* and a leader in developing minimally-invasive Ear, Nose & Throat technologies, announced the U.S. launch of its first-ever AI-powered ENT technology, designed to simplify surgical planning and provide real-time feedback during ENT navigation procedures.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it had won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing systems, an important step to support laboratory testing as the COVID-19 pandemic continues.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced a poster presentation on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers, at the upcoming AACR-NCI-EORTC International Conference.

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has completed its pre-New Drug Application meeting with the United States Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich’s ataxia and reaffirmed its plan to submit an NDA in the first quarter of 2022.

Insulet’s Omnipod ® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data from an interim analysis of an on-going 12-month Phase 3 open-label extension (OLE) study (Study 1601; Part 2) showing that treatment with FINTEPLA® (fenfluramine) oral solution led to a clinically meaningful and sustained reduction in drop seizures in patients with Lennox-Gastaut syndrome (LGS) on antiseizure medications (ASMs)

The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021